## AMENDMENTS TO THE CLAIMS

(list claims as: original, currently amended, cancelled, withdrawn, previously presented, new, or not entered)

1. (Currently Amended) A pharmaceutical composition for ~~vaccination to actively immunize cancer patients for the prevention of the development of metastasis and~~ treatment of cancer disease comprising ~~at least one~~a first antibody directed against the cellular membrane antigen Ep-CAM and at least one vaccine adjuvant.

2. (Previously Presented) The pharmaceutical composition of claim 1, wherein said antibody is of animal origin.

3. (Previously Presented) The pharmaceutical composition of claim 1, wherein said antibody is a monoclonal antibody.

4. (Currently Amended) The pharmaceutical composition of claim 3, wherein said first antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO:1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO:2.

5. (Currently Amended) The pharmaceutical composition of any one of claims 1-3, wherein said first antibody has the same specificity of binding as that antibody defined in claim 4.

6. (Currently Amended) The pharmaceutical composition of claim 1, ~~wherein two or more antibodies, which are~~further comprising at least a second antibody directed against ~~a~~ different membrane antigens or against a different epitopes of said Ep-CAM ~~a~~ membrane antigen~~, are used in combination with each other~~.

7. (Currently Amended) The pharmaceutical composition of claim 1, ~~further comprising at least one vaccine adjuvant~~wherein said first antibody is contained in a dosage range of 0.01 – 4 mg.

8. (Currently Amended) A method of ~~vaccination against~~ treating cancer disease comprising administering to a patient in need thereof the pharmaceutical composition of claim 1 ~~at a dosage in the range of 0.01 to 4 mg antibody~~.

9. (Previously Presented) The method according to claim 8, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.

10. (Currently Amended) ~~A pharmaceutical composition for therapeutic vaccination against cancer comprising at least one~~The method according to claim 8, wherein said first antibody is a monoclonal antibody of animal origin directed against the cellular membrane antigen Ep-CAM, wherein ~~one of~~ said ~~at least one~~first antibody has the amino acid sequence of SEQ ID NO:1 for the variable region of the heavy chain and the amino acid sequence of SEQ ID NO:2 for the variable region of the light chain.

11. (Cancelled) ~~The pharmaceutical composition of claim 10, further comprising at least one vaccine adjuvant.~~

12. (Currently Amended) ~~A~~The method of ~~therapeutic vaccination against cancer comprising administering to a patient in need thereof the pharmaceutical composition of~~ claim 8 or 10 wherein said first antibody is administered at a dosage in the range of 0.01 to 4 mg antibody.

13. (Previously Presented) The method according to claim 12, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.

14. (Currently Amended) ~~A~~ The method ~~of vaccination against cancer comprising administering to a patient in need thereof the pharmaceutical composition of~~according to claim 12 wherein said ~~at a~~ dosage is 0.5~~in the range of 0.01 to 4~~ mg antibody ~~for the prevention of the development of metastasis and treatment of cancer disease~~.